secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2025-11-07T23:59:59+00:00
Accession:  0001023024-25-000107
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

ANI Pharmaceuticals reports record Q3 2025 revenue and raises full-year guidance
--------------------------------------------------------------------------------

- Record quarterly net revenues of $227.8 million, up 53.6% year-over-year.
- Purified Cortrophin Gel net revenues rose 93.8% to $101.9 million.
- Adjusted non-GAAP EBITDA of $59.6 million, up 69.8%.
- Raised 2025 total net revenue guidance to $854M-$873M and adjusted EPS to $7.37-$7.64.
- GAAP diluted EPS of $1.13 vs. net loss of $1.27 per share in prior year period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302425000107/0001023024-25-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302425000107/ani-20251107.htm
  HTML page:      https://secwatch.observer/filing/0001023024-25-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer